JosÃ©e Golay

List of Publications by Year
in descending order

95 papers	6,632 citations	76294 40 h-index	62565 80 g-index
95 all docs	95 docs citations	95 times ranked	7800 citing authors

#	Article	IF	Citations
1	BL-01, an Fc-bearing, tetravalent CD20ÂÃ—ÂCD5 bispecific antibody, redirects multiple immune cells to kill tumors in vitro and in vivo. Cytotherapy, 2022, 24, 161-171.	0.3	2
2	Optimization of therapeutic T cell expansion in G-Rex device and applicability to large-scale production for clinical use. Cytotherapy, 2022, 24, 334-343.	0.3	5
3	A comprehensive report of long-term stability data for a range ATMPs: A need to develop guidelines for safe and harmonized stability studies. Cytotherapy, 2022, 24, 544-556.	0.3	7
4	Identification of Human SARS-CoV-2 Monoclonal Antibodies from Convalescent Patients Using EBV Immortalization. Antibodies, 2021, 10, 26.	1.2	1
5	Key Features Defining the Disposition of Bispecific Antibodies and Their Efficacy In Vivo. Therapeutic Drug Monitoring, 2020, 42, 57-63.	1.0	6
6	Monoclonal Antibody Monitoring: Clinically Relevant Aspects, A Systematic Critical Review. Therapeutic Drug Monitoring, 2020, 42, 45-56.	1.0	12
7	Tolerance to Bone Marrow Transplantation: Do Mesenchymal Stromal Cells Still Have a Future for Acute or Chronic GvHD?. Frontiers in Immunology, 2020, 11, 609063.	2.2	17
8	The Role of Complement in the Mechanism of Action of Therapeutic Anti-Cancer mAbs. Antibodies, 2020, 9, 58.	1.2	41
9	Combined Anti-Cancer Strategies Based on Anti-Checkpoint Inhibitor Antibodies. Antibodies, 2020, 9, 17.	1.2	14
10	Human neutrophils express low levels of FcÎ³RIIIA, which plays a role in PMN activation. Blood, 2019, 133, 1395-1405.	0.6	46
11	Utility of routine evaluation of sterility of cellular therapy products with or without extensive manipulation: Best practices and clinical significance. Cytotherapy, 2018, 20, 262-270.	0.3	15
12	Cord bloodâ€“derived cytokine-induced killer cells combined with blinatumomab as a therapeutic strategy for CD19+ tumors. Cytotherapy, 2018, 20, 1077-1088.	0.3	8
13	Human neutrophils mediate trogocytosis rather than phagocytosis of CLL B cells opsonized with anti-CD20 antibodies. Blood, 2017, 129, 2636-2644.	0.6	86
14	Phase II Study of Sequential Infusion of Donor Lymphocyte Infusion and Cytokine-Induced Killer Cells for Patients Relapsed after Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2017, 23, 2070-2078.	2.0	48
15	The specific Bruton tyrosine kinase inhibitor acalabrutinib (ACP-196) shows favorable in vitro activity against chronic lymphocytic leukemia B cells with CD20 antibodies. Haematologica, 2017, 102, e400-e403.	1.7	41
16	Direct targeting of cancer cells with antibodies: What can we learn from the successes and failure of unconjugated antibodies for lymphoid neoplasias?. Journal of Autoimmunity, 2017, 85, 6-19.	3.0	11
17	Development of advanced therapies in Italy: Management models and sustainability in six Italian cell factories. Cytotherapy, 2016, 18, 481-486.	0.3	7
18	Design and Validation of a Novel Generic Platform for the Production of Tetravalent IgG1-like Bispecific Antibodies. Journal of Immunology, 2016, 196, 3199-3211.	0.4	30

#	Article	IF	Citations
19	Final Analysis of a Multicenter Pilot Phase 2 Study of Cytokine Induced Killer (CIK) Cells for Patients with Relapse after Allogeneic Transplantation. Blood, 2016, 128, 1160-1160.	0.6	5
20	Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy. Haematologica, 2015, 100, 77-86.	1.7	147
21	Clinical grade expansion of MSCs. Immunology Letters, 2015, 168, 222-227.	1.1	41
22	A Multicenter Phase II Study of Sequential Administration of Unmanipulated DLI and Donor Derived Cytokine Induced Killer (CIK) Cells in HSCT Patients, Relapsed of Disease. Blood, 2015, 126, 3160-3160.	0.6	3
23	Frequent occurrence of non-malignant genetic alterations in clinical grade mesenchymal stromal cells expanded for cell therapy protocols. Haematologica, 2014, 99, e94-e97.	1.7	29
24	Direct involvement of CD56 in cytokine-induced killerâ€“mediated lysis of CD56+ hematopoietic target cells. Experimental Hematology, 2014, 42, 1013-1021.e1.	0.2	31
25	Treatment of Graft versus Host Disease with Mesenchymal Stromal Cells: A Phase I Study on 40 Adult and Pediatric Patients. Biology of Blood and Marrow Transplantation, 2014, 20, 375-381.	2.0	181
26	A Novel Method Using Blinatumomab for Efficient, Clinical-Grade Expansion of Polyclonal T Cells for Adoptive Immunotherapy. Journal of Immunology, 2014, 193, 4739-4747.	0.4	24
27	Lessons for the clinic from rituximab pharmacokinetics and pharmacodynamics. MAbs, 2013, 5, 826-837.	2.6	105
28	Givinostat and hydroxyurea synergize inÂvitro to induce apoptosis of cells from JAK2V617F myeloproliferative neoplasm patients. Experimental Hematology, 2013, 41, 253-260.e2.	0.2	30
29	Comment on â€œReduced T-Dependent Humoral Immunity in CD20-Deficient Miceâ€. Journal of Immunology, 2013, 191, 5783-5783.	0.4	0
30	Ofatumumab Is More Efficient than Rituximab in Lysing B Chronic Lymphocytic Leukemia Cells in Whole Blood and in Combination with Chemotherapy. Journal of Immunology, 2013, 190, 231-239.	0.4	95
31	Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximab. Blood, 2013, 122, 3482-3491.	0.6	206
32	The Polo-Like Kinase 1 (PLK1) Inhibitor NMS-P937 Is Effective in a New Model of Disseminated Primary CD56+ Acute Monoblastic Leukaemia. PLoS ONE, 2013, 8, e58424.	1.1	31
33	Massive, Clinical Grade Expansion Of Polyclonal T Cells Using Blinatumomab For Adoptive Autologous Cellular Therapy Of CLL Patients. Blood, 2013, 122, 3272-3272.	0.6	1
34	Small Dose of Rituximab for Graves Orbitopathy: New Insights Into the Mechanism of Action. JAMA Ophthalmology, 2012, 130, 122.	2.6	75
35	Lepidopteran cells, an alternative for the production of recombinant antibodies?. MAbs, 2012, 4, 294-309.	2.6	22
36	The HDAC inhibitor Givinostat modulates the hematopoietic transcription factors NFE2 and C-MYB in JAK2V617F myeloproliferative neoplasm cells. Experimental Hematology, 2012, 40, 634-645.e10.	0.2	36

#	Article	IF	Citations
37	Mechanism of action of therapeutic monoclonal antibodies: Promises and pitfalls of in vitro and in vivo assays. Archives of Biochemistry and Biophysics, 2012, 526, 146-153.	1.4	95
38	Minimally manipulated whole human umbilical cord is a rich source of clinical-grade human mesenchymal stromal cells expanded in human platelet lysate. Cytotherapy, 2011, 13, 786-801.	0.3	104
39	Autologous Mesenchymal Stromal Cells and Kidney Transplantation. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 412-422.	2.2	273
40	Antitumour effects of single or combined monoclonal antibodies directed against membrane antigens expressed by human B cells leukaemia. Molecular Cancer, 2011, 10, 42.	7.9	18
41	Dual-functional capability of CD3+CD56+ CIK cells, a T-cell subset that acquires NK function and retains TCR-mediated specific cytotoxicity. Blood, 2011, 118, 3301-3310.	0.6	188
42	Enhanced killing of human B-cell lymphoma targets by combined use of cytokine-induced killer cell (CIK) cultures and anti-CD20 antibodies. Blood, 2011, 117, 510-518.	0.6	57
43	The in vivo mechanism of action of CD20 monoclonal antibodies depends on local tumor burden. Haematologica, 2011, 96, 1822-1830.	1.7	69
44	Mechanism of Action of Type II, Glycoengineered, Anti-CD20 Monoclonal Antibody GA101 in B-Chronic Lymphocytic Leukemia Whole Blood Assays in Comparison with Rituximab and Alemtuzumab. Journal of Immunology, 2011, 186, 3762-3769.	0.4	198
45	Pleiotropic anti-myeloma activity of ITF2357: inhibition of interleukin-6 receptor signaling and repression of miR-19a and miR-19b. Haematologica, 2010, 95, 260-269.	1.7	36
46	Possible misinterpretation of the mode of action of therapeutic antibodies in vitro: homotypic adhesion and flow cytometry result in artefactual direct cell death. Blood, 2010, 116, 3372-3373.	0.6	41
47	A phase II multiple dose clinical trial of histone deacetylase inhibitor ITF2357 in patients with relapsed or progressive multiple myeloma. Annals of Hematology, 2010, 89, 185-190.	0.8	99
48	Therapeutic efficacy of the pan-cdk inhibitor PHA-793887 in vitro and in vivo in engraftment and high-burden leukemia models. Experimental Hematology, 2010, 38, 259-269.e2.	0.2	12
49	Feasibility and Safety of Adoptive Immunotherapy with CIK Cells after Cord Blood Transplantation. Biology of Blood and Marrow Transplantation, 2010, 16, 1603-1607.	2.0	49
50	M2 Macrophages Phagocytose Rituximab-Opsonized Leukemic Targets More Efficiently than M1 Cells In Vitro. Journal of Immunology, 2009, 182, 4415-4422.	0.4	227
51	Cytokine-induced killer cells are terminallydifferentiated activated CD8 cytotoxic T-EMRA lymphocytes. Experimental Hematology, 2009, 37, 616-628.e2.	0.2	121
52	The washouts of discarded bone marrow collection bags and filters are a very abundant source of hMSCs. Cytotherapy, 2009, 11, 403-413.	0.3	30
53	Complement in antibody therapy: friend or foe?. Blood, 2009, 114, 5247-5248.	0.6	12
54	Hematopoietic Progenitor Cells From Patients with Chronic Mountain Sickness Lack the JAK2V617F Mutation, Show Hypersensitivity to Erythropoietin and Are Inhibited by Statins.. Blood, 2009, 114, 1894-1894.	0.6	3

#	Article	IF	Citations
55	Chemokines and antagonists in non-Hodgkin's lymphoma. Expert Opinion on Therapeutic Targets, 2008, 12, 621-635.	1.5	8
56	Human Mesenchymal Stroma Cells (hMSCs) Expanded with Human Platelets Lysate Are Safe and Effective For the Treatment of Graft Versus Host Disease. Blood, 2008, 112, 1171-1171.	0.6	1
57	The CCL3 Family of Chemokines and Innate Immunity Cooperate In Vivo in the Eradication of an Established Lymphoma Xenograft by Rituximab. Journal of Immunology, 2007, 178, 6616-6623.	0.4	46
58	Repeated infusions of donor-derived cytokine-induced killer cells in patients relapsing after allogeneic stem cell transplantation: a phase I study. Haematologica, 2007, 92, 952-959.	1.7	165
59	FcÂRIIIA and FcÂRIIA polymorphisms do not predict clinical outcome of follicular non-Hodgkin's lymphoma patients treated with sequential CHOP and rituximab. Haematologica, 2007, 92, 1127-1130.	1.7	89
60	Human platelet lysate allows expansion and clinical grade production of mesenchymal stromal cells from small samples of bone marrow aspirates or marrow filter washouts. Bone Marrow Transplantation, 2007, 40, 785-791.	1.3	148
61	Infusion of Donor Derived Cytokine Induced Killer Cells May Induce Clinical Remission with Limited GVHD in Patients Relapsing after Allogeneic Stem Cell Transplantation.. Blood, 2006, 108, 3698-3698.	0.6	1
62	Human Macrophages Phagocytose Rituximab Opsonised Leukemic Cells Via CD16, CD32 and CD64 but Do Not Mediate ADCC.. Blood, 2006, 108, 2507-2507.	0.6	1
63	Potent Inhibition of EEC Colony Formation in JAK2V617F PV and ET by Low Doses of ITF2357, a New Histone Deacetylase Inhibitor.. Blood, 2006, 108, 2702-2702.	0.6	0
64	The role of complement in the therapeutic activity of rituximab in a murine B lymphoma model homing in lymph nodes. Haematologica, 2006, 91, 176-83.	1.7	99
65	The sensitivity of acute lymphoblastic leukemia cells carrying the t(12;21) translocation to campath-1H-mediated cell lysis. Haematologica, 2006, 91, 322-30.	1.7	21
66	Gemtuzumab ozogamicin (Mylotarg) has therapeutic activity against CD33+ acute lymphoblastic leukaemias in vitro and in vivo. British Journal of Haematology, 2005, 128, 310-317.	1.2	52
67	Rituximab induces different but overlapping sets of genes in human B-lymphoma cell lines. Cancer Immunology, Immunotherapy, 2005, 54, 273-286.	2.0	17
68	Characterization of CD20-Transduced T Lymphocytes as an Alternative Suicide Gene Therapy Approach for the Treatment of Graft-Versus-Host Disease. Human Gene Therapy, 2004, 15, 63-76.	1.4	94
69	Functional transfer of CD40L gene in human B-cell precursor ALL blasts by second-generation SIN lentivectors. Gene Therapy, 2004, 11, 85-93.	2.3	35
70	From the bench to the bedside: ways to improve rituximab efficacy. Blood, 2004, 104, 2635-2642.	0.6	494
71	Effect of alemtuzumab on neoplastic B cells. Haematologica, 2004, 89, 1476-83.	1.7	72
72	Characterization of the c-Myb-responsive Region and Regulation of the Human Type I Collagen Î±2 Chain Gene by c-Myb. Journal of Biological Chemistry, 2003, 278, 1533-1541.	1.6	17

#	Article	IF	Citations
73	Complement Activation Determines the Therapeutic Activity of Rituximab In Vivo. Journal of Immunology, 2003, 171, 1581-1587.	0.4	519
74	The toll-like receptor repertoire of human B lymphocytes: inducible and selective expression of TLR9 and TLR10 in normal and transformed cells. Blood, 2003, 102, 956-963.	0.6	344
75	Differential response of human acute myeloid leukemia cells to gemtuzumab ozogamicin in vitro: role of Chk1 and Chk2 phosphorylation and caspase 3. Blood, 2003, 101, 4589-4597.	0.6	76
76	Rituximab-mediated antibody-dependent cellular cytotoxicity against neoplastic B cells is stimulated strongly by interleukin-2. Haematologica, 2003, 88, 1002-12.	1.7	90
77	A Human Immunodeficiency Virus Type 1polGene-Derived Sequence (cPPT/CTS) Increases the Efficiency of Transduction of Human Nondividing Monocytes and T Lymphocytes by Lentiviral Vectors. Human Gene Therapy, 2002, 13, 1793-1807.	1.4	56
78	Acquired immunodeficiency syndrome-associated lymphomas are efficiently lysed through complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity by rituximab. British Journal of Haematology, 2002, 119, 923-929.	1.2	35
79	CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59. Blood, 2001, 98, 3383-3389.	0.6	395
80	A-myb rescues murine B-cell lymphomas from IgM-receptorâ€“mediated apoptosis through c-myctranscriptional regulation. Blood, 2000, 96, 1013-1020.	0.6	16
81	Nucleolin, a Novel Partner for the Myb Transcription Factor Family That Regulates Their Activity. Journal of Biological Chemistry, 2000, 275, 4152-4158.	1.6	54
82	A-Myb Up-regulates Bcl-2 through a Cdx Binding Site in t(14;18) Lymphoma Cells. Journal of Biological Chemistry, 2000, 275, 6499-6508.	1.6	53
83	Genetic Modification of Human T Cells with CD20: A Strategy to Purify and Lyse Transduced Cells with Anti-CD20 Antibodies. Human Gene Therapy, 2000, 11, 611-620.	1.4	126
84	A-myb rescues murine B-cell lymphomas from IgM-receptorâ€“mediated apoptosis through c-myctranscriptional regulation. Blood, 2000, 96, 1013-1020.	0.6	2
85	C-myb, but not B-myb, Upregulates Type I Collagen Gene Expression in Human Fibroblasts. Journal of Investigative Dermatology, 1999, 112, 191-196.	0.3	19
86	Rapid retroviral infection of human haemopoietic cells of different lineages: efficient transfer in fresh T cells. British Journal of Haematology, 1998, 103, 449-461.	1.2	22
87	The DNA Binding Domain of the A-MYB Transcription Factor Is Responsible for Its B Cell-specific Activity and Binds to a B Cell 110-kDa Nuclear Protein. Journal of Biological Chemistry, 1997, 272, 24921-24926.	1.6	13
88	Regulatory domains of the A-Myb transcription factor and its interaction with the CBP/p300 adaptor molecules. Biochemical Journal, 1997, 324, 729-736.	1.7	37
89	The A-Myb Transcription Factor in Neoplastic and Normal B Cells. Leukemia and Lymphoma, 1997, 26, 271-279.	0.6	14
90	Identification of Two Novel Isoforms of the ZNF162 Gene: A Growing Family of Signal Transduction and Activator of RNA Proteins. Genomics, 1997, 42, 268-277.	1.3	11

#	Article	IF	Citations
91	Inducible expression of PTX3, a new member of the pentraxin family, in human mononuclear phagocytes. Cytokine, 1994, 6, 544.	1.4	5
92	Detection of a transcriptional block in the first intron of the human c-myb gene. International Journal of Clinical and Laboratory Research, 1992, 22, 159-164.	1.0	12
93	Mutations in v-myb alter the differentiation of myelomonocytic cells transformed by the oncogene. Cell, 1990, 63, 1287-1297.	13.5	159
94	A single point mutation in the v-ets oncogene affects both erythroid and myelomonocytic cell differentiation. Cell, 1988, 55, 1147-1158.	13.5	99
95	Role of Fc Core Fucosylation in the Effector Function of IgG1 Antibodies. Frontiers in Immunology, 0, 13, .	2.2	24